• Dr. James H. Wyche, PhD was Howard University’s Provost and Chief Academic Officer. He is a distinguished cell and molecular biologist, cancer researcher and university administrator. Spanning four decades, Dr. Wyche’s research and academic career includes appointments as Vice Provost for Academic Affairs and Professor of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center; Vice Provost and Dean of the College of Arts and Sciences and Professor of Biology and Molecular Pharmacology, School of Medicine, University of Miami; Associate Provost and Professor of Medical Science, Department of Molecular Biology, Cell Biology and Biochemistry at Brown University; and Visiting Professor and Scholar-in- Residence at other institutions. Dr. Wyche served as interim president of Tougaloo College during the 2001-2002 academic year.
  • Dr. Calvin Kuo MD, Ph.D. has been an Associate/Assistant Professor of Medicine in the Hematology of Stanford University School of Medicine since 2001. Dr. Kuo serves as Member of Scientific Advisory Board of Athenagen Inc. and CoMentis, Inc. He serves as a Member of Scientific Advisory Board at Silence Therapeutics plc. Dr. Kuo serves as Member of Scientific and Clinical Advisory Board of OncoMed Pharmaceuticals Inc. He is principal investigator on numerous NIH grants. He served as Member of Scientific Advisory Board at Intradigm Corporation. Dr. Kuo has published extensively in journals including Nature, Science, Cell and Nature Medicine and is an inventor on numerous issued and pending patents. He received junior faculty awards from the Burroughs Wellcome and Kimmel Foundations, and has been elected to the American Society for Clinical Investigation. He performed postdoctoral research at Harvard Children’s Hospital. Dr. Kuo received his A.B. from Harvard College and his M.D. and Ph.D. degree from Stanford University.
  • Dr. Jeffrey M. Besterman Ph.D. serves as Chief Scientific Officer and Executive Vice President of Research & Development of Methylgene Inc. Dr. Besterman served as Senior Vice President – Research and Development of MethylGene Inc. since January 1998. Dr. Besterman joined Methylgene Inc. in January 1997. He has over 20 years of drug discovery research and development experience in the pharmaceutical and biotechnology industries. Dr. Besterman served as Head of Oncology Research Section and later as Head of Department of Cell Biology at Glaxo Research Institute, Research Triangle Park, North Carolina. Dr. Besterman led a multi-disciplinary team of over 30 scientists and clinicians in the exploration, identification and early clinical development of Glaxo’s first anti-cancer compound, a topoisomerase I inhibitor. He serves as a member of Scientific Advisory Board of Novothera Biotechnologies Inc., located in Montreal, Quebec. He served as Member of Scientific Advisory Board of Gene Network Science Inc. since April 2008. He has been a Member of the National Cancer Institute’s Special Review Committee for Natural Product Drug Discovery and an external reviewer for the National Science Foundation. He is on the external review board of the Biotechnology Research Institute of the National Research Council of Canada. He is a co-inventor of 22 United States patents and patent applications and 58 peer reviewed scientific publications. He received a B.Sc. in Biology from the State University of New York, Stony Brook and a Ph.D. in Physiology and Biophysics from the University of Vermont School of Medicine and completed his post-doctoral research at Pennsylvania State University’s Medical Center.
  • Dr. Tony Fiorino M.D, Ph.D. serves as the President and Chief Executive Officer of EnzymeRx Inc. Dr. Fiorino served as a Biotechnology Analyst at Citigroup Asset Management. He worked his first few years on Wall Street as Equity Analyst at JP Morgan Chase & Co, Research Division. Dr. Fiorino managed long-short biotechnology portfolios as Pequot Capital Management and Sands Point Partners. He serves as a Director of Stemline. Prior to entering the world of finance, he trained in medicine and dermatology at the Hospital of the University of Pennsylvania after completing the M.D.-Ph.D. program at the Albert Einstein College of Medicine. He was elected to Alpha Omega Alpha, Phi Beta Kappa and Sigma Xi and has authored over 20 publications in the medical and scientific literature. He received a B.S. in Biology from the Massachusetts Institute of Technology.